Drug Trial Radar · NCT06878365
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16
Actual
Start
Jul 29, 2025
Primary completion
Dec 10, 2029
Study completion Dec 20, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with selected type 1 interferonopathies. People can join the study if they have Aicardi-Goutières syndrome (AGS), Coatomer subunit alpha (COPA) syndrome, Familial chilblain lupus (FCL), or another type 1 interferonopathy with a specific gene mutation. The purpose of this study is to find out how BI 3000202 is tolerated in people with selected type 1 interferonopathies. Participants take a lower dose of BI 3000202 as tablets for 4 weeks. Afterwards, they take a higher dose of BI 3000202 as tablets for 36 weeks. They may continue with the study treatment until every participant has completed 40 weeks of treatment (about 9 months). The participants may also continue their regular treatment for their condition during the study. During this study, participants visit the study site 13 times or more, depending on when they start their participation. The doctors check the health of the participants and note any health problems that could have been caused by BI 3000202.
Conditions
- Type 1 Interferonopathies
Interventions
BI 3000202_low doseDrug
BI 3000202\_low dose
BI 3000202_high doseDrug
BI 3000202\_high dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of any treatment-emergent adverse events assessed as related to study drugTime frame: Approximately 72 weeks
Locations
20 sites in 9 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Texas Children's Hospital
Houston, Texas
Universitair Ziekenhuis Gent
Ghent, Belgium
Hôpital Gui de Chauliac
Montpellier, France
Hopital Necker
Paris, France
HOP Tenon
Paris, France
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Barzilai Medical Center
Ashkelon, Israel
ASST degli Spedali Civili di Brescia
Brescia, Italy
Azienda Sanitaria Universitaria Giuliano Isontina
Trieste, Italy
ULS de Santa Maria, E.P.E - Hospital de Santa Maria
Lisbon, Portugal
ULS de Santo Antônio, E.P.E - Centro Hospitalar Universitário de Santo António
Porto, Portugal
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.